EPS for InflaRx N.V. (IFRX) Expected At $-0.40; Kamada LTD. – Ordinary Shares (KMDA) Shorts Raised By 1.79%




August 11, 2018 – By Ira Colvard

Kamada LTD. – Ordinary Shares (NASDAQ:KMDA) had an increase of 1.79% in short interest. KMDA’s SI was 34,100 shares in August as released by FINRA. Its up 1.79% from 33,500 shares previously. With 10,800 avg volume, 3 days are for Kamada LTD. – Ordinary Shares (NASDAQ:KMDA)’s short sellers to cover KMDA’s short positions. The SI to Kamada LTD. – Ordinary Shares’s float is 0.15%. The stock decreased 1.89% or $0.1 during the last trading session, reaching $5.2. About 22,002 shares traded or 6.24% up from the average. Kamada Ltd. (NASDAQ:KMDA) has declined 30.28% since August 11, 2017 and is downtrending. It has underperformed by 42.85% the S&P500. Some Historical KMDA News: 23/04/2018 – Kamada Received Feedback From FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease; 23/04/2018 – KAMADA: FDA ISSUED RESPONSE LETTER ON PROPOSED PHASE 3 PROTOCOL; 15/05/2018 – KAMADA LTD KMDA.TA SEES FY 2018 REVENUE $116 MLN TO $120 MLN; 20/04/2018 New Research on the Global Alpha-1 Antitrypsin Drugs Market| Technavio; 23/04/2018 – Kamada Received Feedback from FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitry; 08/05/2018 – Kedrion Biopharma and Kamada Announce KEDRAB® (Rabies Immune Globulin [Human]) Now Shipping; Distribution Timed to Meet Spring; 15/05/2018 – Kamada Ltd. Had Cash, Cash Equivalents and Short-Term Investments of $47.9M at March 31; 24/04/2018 – TETRA BIO PHARMA INC – UNDER AGREEMENT TERMS, KAMADA WILL BE RESPONSIBLE FOR REGISTERING PRODUCT, MARKETING & DISTRIBUTION, IN ISRAEL; 23/04/2018 – KAMADA UNABLE TO BEGIN PHASE 3 INHALED AAT CLINICAL STUDY IN 2H; 15/05/2018 – KAMADA LTD KMDA.TA SEES FY 2018 REVENUE UP 13 TO 17 PCT

Analysts expect InflaRx N.V. (NASDAQ:IFRX) to report $-0.40 EPS on August, 16.After having $-0.49 EPS previously, InflaRx N.V.’s analysts see -18.37% EPS growth. The stock increased 0.75% or $0.23 during the last trading session, reaching $30.86. About 7,940 shares traded. InflaRx N.V. (NASDAQ:IFRX) has 0.00% since August 11, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical IFRX News: 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results

Another recent and important Kamada Ltd. (NASDAQ:KMDA) news was published by Nasdaq.com which published an article titled: “Kamada Reports Financial Results for Second Quarter and First Six Months of 2018” on August 07, 2018.

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. The company has market cap of $215.43 million. It operates through two divisions, Proprietary Products and Distribution. It has a 16.99 P/E ratio. The companyÂ’s respiratory products include Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital AAT deficiency ; Bramitob to manage chronic pulmonary infection; and FOSTER for the treatment of asthma.

InflaRx N.V. (NASDAQ:IFRX) Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.




Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *